SCHEMBL2408536

SCHEMBL2408536

COc1ccc(Cc2n[nH]c3c2c(=O)n(-c2ccccc2)c2ncccc32)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1A P54750 1/20 0.55
PDE1B Q01064 1/20 0.55
ALDH1A1 P00352 5/20 0.44
PDE4A P27815 6/20 0.43
PDE4B Q07343 5/20 0.43
PDE4C Q08493 5/20 0.43
PDE4D Q08499 5/20 0.43
PTGS2 P35354 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
PKM P14618 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
USP2 O75604 3/20 0.39
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2C9 P11712 3/20 0.39
CYP2C19 P33261 3/20 0.39
TSHR P16473 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2411594 0.96 PDE1A (0.55) PDE1APDE1BALDH1A1PDE4APDE4B
SCHEMBL2409708 0.91 PDE1A (0.52) PDE1APDE1BALDH1A1PDE4APDE4B
SCHEMBL2410839 0.90 PDE1A (0.66) PDE1APDE1BALDH1A1PDE4APDE4B
SCHEMBL2411440 0.90 PDE1A (0.52) PDE1APDE1BALDH1A1PDE4APDE4B
SCHEMBL2411001 0.89 PDE1A (0.52) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL2411232 0.88 CYP3A4 (0.53) PDE1APDE1BALDH1A1PDE4APDE4B
SCHEMBL4192513 0.88 PDE1A (0.52) PDE1APDE1BPDE4APDE4BPDE4C
SCHEMBL2408474 0.87 PDE1A (0.58) PDE1APDE1BALDH1A1PDE4APDE4B
SCHEMBL2409632 0.87 PDE1A (0.58) PDE1APDE1BALDH1A1PDE4APDE4B
SCHEMBL2409264 0.87 PDE1A (0.58) PDE1APDE1BALDH1A1PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559716-B1 PYRAZOLONAPHTHYRIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-09-14 EP disclosed
US-20100093782-A1 Pyrazolonaphthyridine derivatives KANAZAWA HASHIME 2010-04-15 US disclosed
US-7608716-B2 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-10-27 US disclosed
US-20060040972-A1 Pyrazolonaphthyridine derivative ASKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-23 US disclosed
EP-1559716-A1 PYRAZOLONAPHTHYRIDINE DERIVATIVE Grelan Pharmaceutical Co., Ltd. (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040972-A1 Pyrazolonaphthyridine derivative PDE3B, PDE3A, PDE4A PDE1A 28/4885PDE1B 24/4885ALDH1A1 909/4885
US-20100093782-A1 Pyrazolonaphthyridine derivatives PDE3B, PDE3A, PDE4A PDE1A 30/4885PDE1B 23/4885ALDH1A1 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.